• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792).
  
• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
  

PubMed=8198963; DOI=10.1038/bjc.1994.200; PMCID=PMC1969443
Kjonniksen I., Rye P.D., Fodstad O.
Helix pomatia agglutinin binding in human tumour cell lines: correlation with pulmonary metastases in nude mice.
Br. J. Cancer 69:1021-1024(1994)

PubMed=17354236; DOI=10.1002/ijc.22643
Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O.
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Int. J. Cancer 121:199-205(2007)

PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)

PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335
Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A.
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
PLoS ONE 7:E48262-E48262(2012)